The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Official Title: A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Study ID: NCT04165772
Brief Summary: The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hartford Healthcare (Data Collection), Hartford, Connecticut, United States
Baptist Alliance MCI (Data Collection Only), Miami, Florida, United States
Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth - Limited Protocol Activities, Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen - Limited Protocol Activities, Montvale, New Jersey, United States
New York Cancer and Blood Specialists, Babylon, New York, United States
Memorial Sloan Kettering Commack - Limited Protocol Activities, Commack, New York, United States
Memorial Sloan Kettering Westchester - Limited Protocol Activities, Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Nassau - Limited Protocol Activities, Uniondale, New York, United States
Lehigh Valley Health Network (Data Collection Only), Allentown, Pennsylvania, United States
Name: Andrea Cercek, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR